ライフサイエンスコーパス: mucosal healing

1 at epithelial TNFR signaling participates in mucosal healing.

2 ammatory bowel diseases (IBD) and intestinal mucosal healing.

3 to mice with induced colonic wounds promoted mucosal healing.

4 mptoms of diarrhea or abdominal pain despite mucosal healing.

5 0.81 for endoscopic remission, and 0.78 for mucosal healing.

6 atric patients with IBD suggesting a role in mucosal healing.

7 examined, negative EMA most reliably predict mucosal healing.

8 hibition of enterocyte migration and reduced mucosal healing.

9 e treated with pantoprazole until esophageal mucosal healing.

10 ssue injury while improving wound repair and mucosal healing.

11 healing vs patients with asymptomatic IBD in mucosal healing.

12 improving anabolic metabolism and enhancing mucosal healing.

13 reased susceptibility to injury and impaired mucosal healing.

14 ithelial differentiation, proliferation, and mucosal healing.

15 ion and for the sheet migration required for mucosal healing.

16 ; endoscopic remission, 44 vs 489 mg/kg; and mucosal healing, 127 vs 753 mg/kg.

17 re present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD, 17.4% with U

18 golimumab were in clinical remission and had mucosal healing (27.8% and 42.4%) than patients given pl

19 %) achieved clinical remission (P < .05) and mucosal healing (41% GZMA(high) vs 19% GZMA(low) and 44%

20 owever, out of 12 EMA-positive children with mucosal healing, 9 subsequently turned EMA-negative.

21 e involved in the development of colitis and mucosal healing after colonic inflammation.

22 ustained epithelial cell apoptosis precluded mucosal healing and decreased animal survival.

23 nt that treatment targets in IBD will ensure mucosal healing and deep remission.

24 Mice lacking ITF had impaired mucosal healing and died from extensive colitis after or

25 In patients with CD, mucosal healing and endoscopic response (defined as a de

26 At week 26, mucosal healing and endoscopic response were achieved in

27 kers of sustained small intestinal growth or mucosal healing and evaluation of intestinal epithelial

28 group 3 innate lymphoid cells (ILC3) promote mucosal healing and maintain barrier integrity, but how

29 ith colitis given anti-TNF had near complete mucosal healing and Rag1(-/-) mice given an isotype cont

30 epithelial homeostasis and the promotion of mucosal healing and suggest that recombinant MFG-E8 may

31 aling may represent a novel means to promote mucosal healing and to maintain intestinal homeostasis a

32 s of remission, therapeutic goals (including mucosal healing) and outcomes that matter to patients, s

33 y higher in patients with clinical response, mucosal healing, and/or clinical remission than in patie

34 In patients with ulcerative colitis, mucosal healing appears to be an important predictor of

35 In patients with Crohn's disease, mucosal healing appears to predict future endoscopic act

36 he literature concerning the significance of mucosal healing as a predictor of future clinical and en

37 activity index, and inclusion of endoscopic mucosal healing as the remission definition all were ass

38 y end points included clinical remission and mucosal healing at both weeks 30 and 54.

39 percent of patients receiving adalimumab had mucosal healing at week 12 (the primary end point) versu

40 Mucosal healing at week 16 occurred in 62.8% (49 of 78)

41 Mucosal healing at week 26 was associated with CFREM at

42 100 mg golimumab had clinical remission and mucosal healing at weeks 30 and 54.

43 able for monitoring treatment response, with mucosal healing being a major treatment goal.

44 of IECs in mice with colitis and accelerates mucosal healing by activating STAT1.

45 atrophy was compared with that of those with mucosal healing by using Cox regression.

46 The primary endpoint was mucosal healing (CDEIS <4) with absence of deep ulcers 4

47 increased CCN1 expression may be involved in mucosal healing during colitis.

48 (NK-1R), both in vitro and in vivo, promote mucosal healing during recovery from colitis by stimulat

49 of defense systems and factors that enhance mucosal healing, focusing on findings that elucidate new

50 gut epithelial surface, where they stimulate mucosal healing following acute injury.

51 apy in achieving optimal growth and inducing mucosal healing for pediatric Crohn's disease.

52 n this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability.

53 adalimumab for induction and maintenance of mucosal healing in 135 adults with moderate to severe il

54 Exogenous KGF has a key role in mucosal healing in an experimental model of colitis in r

55 apoptosis may be an important mechanism for mucosal healing in anti-TNF-treated CUC patients.

56 uR deficiency in the pathogenesis of delayed mucosal healing in certain pathological conditions.

57 ormone reduces disease activity and promotes mucosal healing in colitis and can activate SHP-2.

58 lay an important role in gut homeostasis and mucosal healing in inflammatory bowel disease.

59 igration, whereas deletion of MFG-E8 impeded mucosal healing in mice with sepsis.

60 y of adalimumab for inducing and maintaining mucosal healing in patients with Crohn's disease (CD).

61 tion may be an effective strategy to promote mucosal healing in patients with UC.

62 of MKP-1 might be the basis for the impaired mucosal healing in PHT gastric mucosa.

63 echanisms that control tissue protection and mucosal healing in response to intestinal damage remain

64 D1b receptor agonists might be used to help mucosal healing in the gastrointestinal tract.

65 Recent evidence suggests that mucosal healing is also an important predictor of long-t

66 Assessment of mucosal healing is an important tool in the management o

67 is effective, well tolerated and that early mucosal healing is associated with decreased risk of col

68 -up intestinal biopsy, performed to document mucosal healing, is unknown.

69 Because enterocytes migrate together, mucosal healing may require interenterocyte communicatio

70 Among group B children, 88.7% showed mucosal healing (median 2.2 years after primary diagnosi

71 Mucosal healing might alter midterm and long-term outcom

72 Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with

73 -up period of 1 year and was associated with mucosal healing observed in follow-up endoscopy.

74 After remission of SJS/TEN, a complete ENT mucosal healing occurred in 36 patients (74%) at 2 month

75 ures of inflammatory bowel disease, complete mucosal healing occurs in fewer than 50% of patients.

76 6 [95% credible interval, 1.22 to 4.63]) and mucosal healing (odds ratio, 2.02 [95% credible interval

77 mast cell protease 4 did not restore normal mucosal healing or reduce efficiently inflammation after

78 y responded (clinical remission and complete mucosal healing) or did not respond to infliximab.

79 MCs were localized in areas of mucosal healing rather than damaged areas where they deg

80 Because ERK2 is crucial for mucosal healing, reduced ERK2 activation resulting from

81 e downstream processes by which TLR4 impairs mucosal healing remain incompletely understood.

82 78 [CI, 2.71 to 5.12]) than among those with mucosal healing (SIR, 1.50 [CI, 0.77 to 2.62]).

83 Multiple factors affect oral mucosal healing, such as the persistence of an inflammat

84 bination therapy led to significantly better mucosal healing than azathioprine monotherapy.

85 eceive adalimumab are more likely to achieve mucosal healing than those given placebo.

86 clinical responses, clinical remissions, and mucosal healings than placebo for induction therapy.

87 Intestinal inflammation can impair mucosal healing, thereby establishing a vicious cycle le

88 The transcription factor KLF5 regulates mucosal healing through its effects on epithelial prolif

89 ggest a physiologic role for TFF2 to promote mucosal healing through the stimulation of proliferation

90 eability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in muc

91 Persistent villous atrophy compared with mucosal healing was associated with an increased risk fo

92 Mucosal healing was defined as absence of ulcers.

93 Mucosal healing was defined as CD Endoscopic Index of Se

94 re </=2, with no individual subscore >1, and mucosal healing was defined as endoscopic score </=1.

95 Mucosal healing was reassessed by ileocolonoscopy at wee

96 stinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal perme

97 kinase (ERK) plays a pivotal role in gastric mucosal healing, we investigated whether ERK activation

98 At week 52, rates of mucosal healing were 24% and 0, respectively (P < .001).

99 oing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specifi